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Summary Following the demonstration of efficacy, tolerability and quality-of-life benefits of raltitrexed ('Tomudex'), principally in advanced
colorectal but also in other cancers, an extensive evaluation of combination therapy with other agents in patients with colorectal and other
tumour types is being undertaken. This work has been prompted by preclinical observations of enhanced activity of raltitrexed when
coadministered with other cytotoxic agents or radiotherapy and by preliminary results showing the activity of raltitrexed in patients with cancers
other than colorectal. Raltitrexed is currently being investigated as monotherapy in phase and 11 cancer studies, including head and neck
cancer, hormone-resistant prostate cancer, paediatric and adult leukaemias and solid tumours, and soft tissue sarcoma. In addition, phase
clinical trials are evaluating the drug in combination with taxanes (paclitaxel) in solid tumours, anthracyclines (doxorubicin) in gastric
carcinoma, topoisomerase inhibitors (CPT-11) and 5-fluorouracil (both infusion and bolus regimens) in advanced colorectal cancer, platinum
compounds (oxaliplatin and cisplatin) in avariety oftumours and radiotherapy in rectal cancer. Preliminary reports indicate good tolerability and
acceptability of the combinations being investigated, with no dose-limiting toxicity being reported to date, and some early indications of efficacy.
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Raltitrexed ('Tomudex') has been designed to inhibit directly and
non-competitively a specific molecular target, thymidylate
synthase (TS). The development of TS inhibitors for cancer
therapy has been described in several reviews (Jackman and
Judson, 1996; Touroutoglou and Pazdur, 1996; Rustum et al,
1997). TS converts deoxyuridine monophosphate (dUMP) into
thymidine monophosphate (TMP), after which other enzymes
convert TMP to thymidine triphosphate, a key requirement for
DNA synthesis. 5-Fluorouracil (5-FU) is metabolized to 5-fluoro-
deoxyuridine monophosphate (FdUMP), which forms an inactive
complex with TS and stops the synthesis of TMP by blocking
access of dUMP to TS. However, the concentration of dUMP in
the cell then rises to the point at which it is able to overcome
FdUMP. 5-FU is also converted to other metabolites that can affect
RNA and subsequently protein synthesis; these may enhance anti-
tumour activity but may also cause toxicity. Unlike 5-FU,
raltitrexed inhibits TS directly and does notrequire the presence of
a second agent (Figure 1) (Jackman et al, 1995). Furthermore, the
drug is specific for TS and does not appear to affect other cellular
pathways. Raltitrexed is taken up into cells by the reduced folate
carrier system in the cell membrane. This carrier is found more
frequently on some tumour cells, an observation that may help to
explain the selectivity of raltitrexed. While raltitrexed is active in
its parent form, once inside the cell it is rapidly converted into
polyglutamated forms. These polyglutamates are more potent
inhibitors of TS than the parent drug, are retained within cells for
longer and cause enhanced and extended inhibition of TS
(Jackman et al, 1991, 1995), which permits a more convenient
(once every 3 weeks) dosing schedule than is possible for regi-
mens based on 5-FU.
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MONOTHERAPY FOR ADVANCED COLORECTAL
CANCER
Raltitrexed is now available in more than ten countries for the
first-line treatment of advanced colorectal cancer (CRC). Until
recently, the only effective chemotherapy for this disease was 5-
FU, administered in conjunction with a modulating agent [usually
leucovorin (LV)]. Chemotherapy regimens based on 5-FU have
prolonged survival significantly compared with best supportive
care alone in advanced CRC (Nordic Gastrointestinal Tumour
Adjuvant Therapy Group, 1992; Scheithauer et al, 1993; Allen-
Mersh et al, 1994), but complex and inconvenient administration
schedules are associated with the use ofthis drug.
The efficacy of raltitrexed as monotherapy in patients with
advanced CRC has been shown in three phase III clinical studies
(Cunningham et al, 1996a; Harper and Study Group, 1997; Kerr,
1997; Pazdur and Vincent, 1997) in which raltitrexed was
compared with two standard 5-FU-based regimens. Two inter-
national trials, studies 3 (439 patients) and 12 (495 patients),
compared raltitrexed 3 mg m-2 once every 3 weeks with 5-FU
425 mg m-2 plus LV 20 mg m-2 (Mayo regimen) and 5-FU
400 mg m-2 plus LV 200 mg m-2 (Machover regimen), respec-
tively, every 4-5 weeks. A North American trial, study 10, origi-
nally randomized patients to three treatment arms: raltitrexed 3
and 4 mg m-2 and 5-FU + LV (Mayo regimen). The 4 mg m-2 dose
of raltitrexed was discontinued because of unacceptable toxicity,
and the subsequent analysis was based on a two-group comparison
in a total of 427 patients. Objective response rates, times to
progression and survival data are shown in Table 1. Palliative
benefits of treatment included weight gain and improvements in
performance status and disease-related symptoms, and were seen
in all trials, with the greatest benefits being seen in patients who
achieved complete or partial remission or disease stabilization
(45-70% of all patients).
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FUTURE POTENTIAL
Speculation with regard to the potential clinical use of raltitrexed
in other tumours, in combination with other cytotoxic agents or as
adjuvant therapy in colon cancer, has prompted further evaluation
in these settings. Raltitrexed has already been evaluated as
monotherapy in the management ofother tumour types in phase II
trials (Cunningham et al, 1996b). Complete and partial responses
were seen in patients with breast (26%), ovarian (7%), non-small-
cell lung (9%) and pancreatic cancer (12%). Although there were
no complete or partial responses to treatment with raltitrexed in a
phase II study of 33 patients with hepatocellular carcinoma, there
were 'good' minor responses in two patients (8%), one of whom
had a marked and sustained decrease (from 188 to 5 gg 1-') in
plasma ax-fetoprotein levels (Rougier et al, 1997). Three other
patients also showed decreases of at least 25% in plasma levels of
this tumour marker (range 60-98%).
The concept of combination therapy offers three opportunities
for improved efficacy. Firstly, drugs with non-overlapping toxici-
ties that have already shown activity against a particular tumour
type may be coadministered. Secondly, agents that act at different
phases of the cell cycle may be used, which leads to biochemical
synergy. Thirdly, agents that act at the same phase ofthe cell cycle,
but through differing mechanisms, may be used; this leads to an
additive effect (Figure 2). For example, raltitrexed and 5-FU both
act at S-phase through their inhibition of TS; however, each drug
enters the cell and achieves this effect in a different way. These,
and other drugs in combination, will be considered in more detail
in the following discussion.
COMBINATION TREATMENTS UNDER
INVESTIGATION
The clinical trials currently underway to investigate the efficacy of
raltitrexed in a range ofdifferent tumour types are shown in Table
2. Treatments to be discussed in detail are as follows: raltitrexed
with taxanes (e.g. paclitaxel); raltitrexed with anthracyclines (e.g.
doxorubicin); and combinations in colon and rectal cancer that
include raltitrexed with platinum compounds (e.g. oxaliplatin,
cisplatin); raltitrexed with topoisomerase I inhibitors (e.g. CPT-
11); raltitrexed with 5-FU (bolus and infusion); and raltitrexed
with radiotherapy.
Raltitrexed with taxanes
The taxanes, which include paclitaxel and docetaxel, block cell
replication at G2/M phase by inhibiting normal spindle formation
through the formation of abnormally stable microtubule bundles
(Schiff and Horwitz, 1980; Horwitz, 1995). The most impressive
clinical activity of paclitaxel has been seen in advanced ovarian
and breast cancers (Rowinsky, 1995). Phase II data show similar
activity for docetaxel, with both drugs being active in advanced
breast cancer refractory to anthracycline therapy (Rowinsky et al,
1990; Rowinsky and Donehower, 1995; Seidman 1995). Anti-
tumour activity has also been observed in a range of tumours that
are generally refractory to other treatments, including non-small-
and small-cell lung, head and neck, oesophageal, bladder and germ
cell cancers as well as lymphoma and Kaposi's sarcoma
(Rowinsky et al, 1990; Rowinsky and Donehower, 1995).
The taxanes show toxicity profiles that differ from that of
raltitrexed, with myelosuppression being their most notable
side-effect. Paclitaxel induces neutropenia, hypersensitivity reac-
tions, peripheral neuropathy and cardiac rhythm disturbances
(Rowinsky and Donehower, 1995; Ratain, 1997). Docetaxel is
associated with fluid retention and skin toxicity and, although
nausea, vomiting and diarrhoea may be observed, severe gastro-
intestinal toxicity is rare (Ratain, 1997). Thus, as well as being
of mechanistic interest as candidates for combination with
raltitrexed, these agents also have toxicity profiles that largely do
not overlap with that ofraltitrexed.
As shown in Table 2, combination therapy with raltitrexed and
paclitaxel is currently under investigation in a phase I clinical
study designed to determine maximum-tolerated dose (MTD) in
patients with refractory solid tumours. This single-centre USA
study is recruiting patients who have undergone previous standard
treatment and includes a follow-up to assess safety [adverse events
(WHO criteria) and haematology and biochemistry]. Dose levels
of raltitrexed 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mg m-2 are being
administered with paclitaxel at a fixed dosage of 175 mg m-2 every
3 weeks (this is the highest recommended dosage of paclitaxel in
the USA; further escalation ofraltitrexed dose in 0.5 mg m-2 incre-
ments will be undertaken ifthe MTD is notreached at 3.0 mg m-2).
Future development may include combination of the agreed
dosage of raltitrexed plus paclitaxel with carboplatin in a follow-
on phase I study that could lead to randomized comparisons with
standard therapy in patients with non-small-cell lung cancer.
Raltitrexed with anthracyclines
The anthracyclines, which include doxorubicin and daunorubicin,
have been in clinical use since the 1960s and form one ofthe most
commonly used groups of anti-cancer drugs. They have several
postulated mechanisms of action, the most important of which is
believed to be interference with the function of the enzyme topo-
isomerase II (Ratain, 1997). A representation of the action of
anthracyclines is shown in Figure 3.
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Figure 1 Sites of action of raltitrexed, 5-fluorouracil (5-FU) and
methotrexate (MTX). dUMP, deoxyuridine monophosphate; FdUMP,
5-fluorodeoxyuridine monophosphate; TMP, thymidine monophosphate
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Table 1 Clinical efficacy results from studies of raltitrexed in advanced colorectal cancer
Study3 Study 10 Study 12
Parameter Raltitrexed (n = 223)5-FU + LV (n = 216) Raltitrexed (n = 217) 5-FU + LV (n= 210) Raltitrexed (n = 247) 5-FU + LV(n = 248)
Complete response rate (%) 3.6 3.7 2.8 1.4 3.2 3.6
Partial response rate (%) 15.7 13.0 11.5 13.8 15.4 14.5
Time to progression (months) 4.8 3.6 3.1 5.3*** 3.9 5.1**
Survival (months) 10.1 10.2 9.7 12.7* 10.7 11.8
*P= 0.01; **P< 0.005; ***P< 0.0001 between groups.
Mitosis: cell division Resting phase
Figure 2 The cell cycle and some anti-cancer treatments that act on its
various phases. 5-FU, 5-fluorouracil
Dose-limiting toxicity ofthe anthracyclines manifests chiefly as
myelosuppression, with neutrophils being primarily affected.
Gastrointestinal toxicity, including mucositis, is also common
(Ratain, 1997). It should be noted that mucositis is markedly less
severe with raltitrexed than with 5-FU (Cunningham et al, 1996a)
which may make raltitrexed the more suitable of these two TS
inhibitors for such a combination study. Anthracyclines are also
associated with acute and chronic cardiotoxicity, notably dose-
dependent congestive cardiomyopathy.
A phase I multicentre study of raltitrexed 2.5 mg m-2 with
doxorubicin every 3 weeks in patients with locally advanced or
metastatic gastric cancer is being undertaken by the National
Cancer Institute of Canada (NCIC). Up to 40 patients with no
previous systemic treatment will be recruited to this study, the aim
of which is to evaluate objective tumour response and safety. To
date, patients have received either 30 or40 mg m-2 ofdoxorubicin,
with no dose-limiting toxicity (DLT) seen at level 1 (raltitrexed
2.5 mg m-2 with doxorubicin 30 g m-2). Further dose escalations
are planned. Future developments include a study ofraltitrexed in
combination with the second-generation anthracycline epirubicin.
Raltitrexed with platinum compounds
Cisplatin (Figure 4) was the first anti-cancer platinum compound
to enter clinical trials in the 1970s and remains important in the
curative therapy ofadvanced germ cell tumours. Several thousand
platinum complexes have been synthesized over the last 20 years
in attempts to develop less toxic, non-cross-resistant or oral
analogues, one ofwhich is oxaliplatin (McKeage, 1995).
Platinum-containing compounds act by cross-linking (adduc-
tion) with DNA strands (cisplatin reacts readily with the purine N7
position to form avariety ofmono- andbifunctional DNA adducts,
the majority of which are intrastrand cross-links) (Ratain, 1997).
The resulting damage to DNA strands (including local kinking and
unwinding) causes inhibition of transcription and replication
(Figure 5). Cisplatin is the longest-established drug of this type
but is associated with severe toxicity (nausea and vomiting,
nephrotoxicity, myelosuppression, neurotoxicity and ototoxicity).
Oxaliplatin is a third-generation compound that causes minimal
myelosuppression and has not been associated with nephrotoxi-
city; toxicity manifests mainly as nausea and vomiting, diarrhoea
and neurotoxicity (Ratain, 1997). These agents have been
combined with 5-FU in pretreated patients with resistant tumours,
most notably oxaliplatin in patients with advanced CRC (Levi et
al, 1992, 1994, 1995; de Gramont et al, 1994).
Platinum compounds and raltitrexed therefore act by different
mechanisms: platinum compounds by damaging DNA and
raltitrexed by interfering with DNA synthesis and repair. The
different toxicity profiles of these compounds add further support
to the rationale for their use in combination. Indeed, results of in
vitro cell line work indicate synergy between both oxaliplatin and
5-FU in human colonic (HT-29), ovarian (2008, A2780) and
hormone-refractory breast (MDA-MB-231) cancer cells (Kelland
et al, 1995; Ackland et al, 1996; Raymond et al, 1996).
Simultaneous 72-h exposure of A2780 cells to raltitrexed and
cisplatin showed synergism at some concentration ratios and
additivity or antagonism at others (Table 3).
A phase I dose escalation study is currently under way in France
in patients with advanced cancer refractory to previous therapy.
Fifteen patients with a variety of tumour types (mesothelioma,
small-cell lung, ovarian, stomach, adrenal and duodenal/jejunum
cancer) have been recruited to five dosage levels (all treatments
given once every 3 weeks) (Table 4). The study is designed to
determine the recommended dosage and side-effect profile (with
particular reference to haematological, biochemical and neurolog-
ical toxicities) for raltitrexed with oxaliplatin. In addition, a phase
I study ofraltitrexed in combination with cisplatin in patients with
non-small-cell lung cancer is being carried out in Germany; three
patients have so far been recruited to the first dose level of
raltitrexed 2.6 mg m-2 with cisplatin 60 mg m-2. To date, no DLT
has been reported in either study.
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Table 2 Ongoing study programme for raltitrexed
Drug(s) Malignancy Investigator Country Phase Regimen
Head and neck
Advanced soft tissue sarcoma
Squamous cell head and neck
Hormone-resistant prostate
Advanced paediatric cancers
Paediatric leukaemia
Raltitrexed + paclitaxel Solid tumours
Zalcberg J, Clarke S Austr;
EORTC Europ
Samlowski WE and the South USA
West Oncology Group
Burch PA and the North Central USA
Cancer Treatment Group
Adamson PC and the Childrens USA
Cancer Group
Weitman SD and the Paediatric USA
Oncology Group
Vokes EE USA
ralia 11 3 mg m-2 every 3 weeks
pe 11 3mg m-2 every3 weeks
11 3mgm-2 every 3 weeks
3 mg m-2 every 3 weeks
2, 2.5, 3, 3.5 or 4 mg m-2 every 3
weeks (further escalations
allowed if MTD not reached at
these dosages)
2.5, 3,3.6or4.3mgm-2every3
weeks (further escalations
allowed if MTD not reached at
these dosages)
Raltitrexed 0.5,1, 1.5, 2, 2.5 and
3.0 mg m-2 + paclitaxel
175 mg m-2 every 3 weeks.
Further raltitrexed dose
escalations permitted if MTD not
reached
Raltitrexed + doxorubicin
Raltitrexed + CPT-11
Raltitrexed + oxaliplatin
Raltitrexed + cisplatin
Raltitrexed + 5-FU bolus
Raltitrexed + 5-FU
infusion
Raltitrexed + radiotherapy
Gastric Seymour L
Advanced colorectal
Small-cell lung, mesothelioma,
ovarian, stomach, adrenal,
duodenal
Non-small-cell lung
Advanced colorectal
Advanced colorectal
Rectal
Canada Raltitrexed 2.5 mg m-2 +
doxorubicin 30 or 40 mg m-2
every 3 weeks
Cunningham D
Armand JP
Manegold C
Schwartz GK
Harstrick A
Price P
UK Raltitrexed 2, 2.6 or 3 mg m-2 +
CPT-11 175, 200, 250, 300 or
350 mg m-2 every 3 weeks
France Raltitrexed 2, 2.5 or 3 mg m-2 +
oxaliplatin 85, 100 or 130 mg m-2
every 3 weeks
Germany Raltitrexed 2.6 mg m-2 + cisplatin
60 mg m-2 every 3 weeks
USA Raltitrexed 1.5, 2, 2.5 or 3 mg m-2
every 3 weeks + 5-FU to
1500 mg m-2 by rapid i.v. infusion
24 h after raltitrexed
Germany Raltitrexed 2.6 or 3 mg m-2 on
weeks 2 and 5 + 5-FU 1200,
1600, 2000 or 2400 mg m-2 over
24 h on weeks 1, 2, 3, 4 and 5
UK Raltitrexed 2, 2.6 or 3 mg m-2;
2 doses - days 1 and 22 +
radiotherapy 28 fractions of 1.8 Gy
five times per week for 5-6 weeks
MTD, maximum-tolerated dose.
PHASE I STUDIES IN COLON AND RECTAL
CANCER
Raltitrexed with topoisomerase inhibitors
Growing and dividing cells must be able to copy their DNA, either
to produce an RNA template for protein synthesis (transcription)
or to form more DNA for daughter cells (replication). In both
cases, the DNA double helix must be unwound and the strands
separated to expose single short sections that act as templates.
When this happens, torsional strain is placed on neighbouring
sections, and the enzyme topoisomerase I acts to relieve this strain.
The enzyme binds covalently to DNA and causes a transient
single-strand break that allows the broken ends to rotate and so
release the torsional strain. The break is then religated and the
process of cell division can continue. Topoisomerase I inhibitors,
such as CPT-11 (irinotecan), prevent the religation step and leave
the enzyme bound to DNA at a single-strand break (Armand et al,
1995; Verweij et al, 1995). Further DNA unwinding cannot then
occur, transcription and replication stop, and cell division ceases
(Figure 6).
A number of topoisomerase I inhibitors have been synthesized:
these include CPT- 1, topotecan, GI 147211, 9-aminocampto-
thecin and DX 8951. Of these, CPT- 1I has shown activity
against CRC in phase II trials, with response rates of 15-32% in
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Figure 5 Action of platinum compounds on DNA
Figure 3 Action of anthracycline drugs on protein synthesis
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Figure 4 Structural formula of cisplatin. Note the square-planar
configuration with ammonia and chloride substitutions in the cis orientation
Table 3 Degrees of synergism and additivity with varying concentration
ratios of raltitrexed and cisplatin in human ovarian A2780 cancer cells
(Kelland et al, 1995)
Concentration ratio - raltitrexed:cisplatin 10:1 1:1 1:10 1:100
Combination index (CI) 0.81 1.6 0.98 0.84
Combination index (Cl) is determined from regression analysis of growth
inhibition data. Cl < 1 indicates synergism; Cl = 1 indicates additivity; Cl > 1
indicates antagonism.
synergistic activity, with the magnitude of potentiation being
greater when short-term (4-h) exposure was used and SN 38 given
first. Higher relative doses ofraltitrexed also resulted in increased
cytotoxicity (Table 5). These data indicate the importance of
optimal scheduling of drug combinations and formed the basis of
the schedule selected for the phase I clinical study described later
in this section.
Dose-limiting toxicities in phase II trials of CPT- 11 have been
diarrhoea and neutropenia. Nausea and vomiting also occur
frequently. However, mucositis was rare with this drug (Rougier
and Bugat, 1996). The major toxicities associated with raltitrexed
were elevated transaminases and diarrhoea (Zalcberg, 1997).
These-toxicity profiles partly overlap, and a phase I dose escalation
study is under way to optimize dosages ofthese drugs when given
in combination. This single-centre UK study in 25 patients with
advanced metastatic CRC resistant to infusional 5-FU will deter-
mine MTD, toxicity and objective response rate. CPT-11 is admin-
istered 1 h before raltitrexed, and drugs are administered once
every 3 weeks. Dosage levels are shown in Table 6. Partial remis-
sion of disease has been reported for a patient on the highest dose
level, and there have been no observations ofmajor toxicity, which
leads to the interesting speculation that raltitrexed may moderate
the toxicity ofCPT-11.
previously untreated and 5-FU-resistant tumours (Armand et al,
1995; Rougier and Bugat, 1996; Van Cutsem et al, 1996). As both
raltitrexed and CPT-11 have demonstrated activity against CRC,
and are known to act by different molecular mechanisms, there is a
possibility that synergism may be observed ifboth drugs are given
together in patients with this disease.
Preclinical in vitro studies carried out in cloned human cell lines
with raltitrexed and SN 38, the active metabolite of CPT-11, have
shown evidence of synergism between the two agents (Aschele et
al, 1995, 1996a and b). In particular, Aschele et al (1996a) showed
that sequential rather than simultaneous administration resulted in
Raltitrexed with 5-FU
As described previously, raltitrexed and 5-FU have both been
shown in clinical studies to be effective as single agents in the treat-
ment of advanced CRC. Both drugs share TS as a common target,
but raltitrexed inhibits this enzyme directly and specifically. Some
metabolites of 5-FU are incorporated into RNA, so 5-FU inhibits
both DNA and RNA synthesis. The degree of RNA inhibition
appears to be schedule dependent (Sobrero et al, 1997). A combina-
tion of the two drugs may therefore produce a more complete
blockade of TS than either agent alone. Furthermore, increased
activity against heterogeneous cell populations might be conferred
by the exclusivity of modes of drug uptake and metabolism. As
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Table 4 Three-weekly dosages of raltitrexed and oxaliplatin in combination
in patients with advanced cancer
Dosage level -I I II IlIl IV
Oxaliplatin (mg m-2) 85 85 110 110 130
Raltitrexed (mg m-2) 2.0 2.5 2.5 3.0 3.0
Closing inhibidon
CON death
Figure 6 The action of topoisomerase on DNA transcription
both drugs are active in advanced CRC, combination of the two
would be expected to enhance their respective cytotoxic effects.
Evidence from preclinical studies supports the use of combina-
tion therapy with raltitrexed and 5-FU. Raltitrexed is already
known to increase the incorporation offluorouracil phosphate into
RNA if administered before 5-FU (Izzo et al, 1995). Preclinical
studies with human CRC cell lines HT-29 and HCT-8 have shown
synergistic interactions between raltitrexed and 5-FU (Chang et al,
1994; Izzo etal, 1995; Kimbell etal, 1996). When 5-FU was given
for 1 h before 24-h incubation with raltitrexed, strong antagonism
of the cytotoxic effect was seen with high doses of 5-FU and low
doses of raltitrexed. However, low doses of 5-FU and high doses
ofraltitrexed resulted in synergism. Harstrick (1995) has reported
that an overall pattern ofadditivity is shown by isobole analysis of
this sequence (Figure 7). Notably, reversal ofthe schedules, so that
raltitrexed was used first, caused synergism for all drug ratios
(Izzo, 1995).
The main toxic effects of 5-FU are mucositis and diarrhoea,
myelosuppression and skin disorders. As well as diarrhoea,
raltitrexed is associatedwith leucopenia, and somyelosuppression is
common to both agents. However, the severity ofthis effect may be
reduced if5-FU is given as aprolonged infusion; one ofthe clinical
trials described in this section takes advantage ofthis. Furthermore,
mucositis and leucopenia appear to be markedly less frequent and
less severe with raltitrexed than with 5-FU (Zalcberg, 1997).
A review ofpreclinical and clinical literature on the anti-tumour
and toxic effects of5-FU has indicated that this drug appears to act
in different ways when given according to different dose sched-
ules, most notably bolus or continuous infusion (Sobrero, 1997).
To investigate this premise, two phase I clinical studies of
raltitrexed in combination with 5-FU in patients with advanced
CRC are under way. The first, which is being conducted in the
USA, involves patients with advanced metastatic or recurrent,
unresectable colorectal cancer (Schwartz et al, 1997). Objectives
are to determine the MTD, toxicity and anti-tumour activity of
raltitrexed followed after 24 h by 5-FU given as a rapid intra-
venous infusion. Follow-up is 28 days after the final dose and
tolerability is to be assessed in terms ofhaematology, biochemistry
and adverse event reports. Dosage levels have been raltitrexed0.5,
1.0, 1.5, 2.0, 2.5 or 3.0 mg m-2 with 5-FU 900 mg m-2 every
3 weeks; these have recently been increased to raltitrexed
3.0 mg m-2 with 5-FU 1200 mg m-2, with the intention to further
increase the 5-FU dose to 1500 mg m-2. Preliminary data in 12
patients who have received raltitrexed at a dose of up to 2.0 mg
m-2 showed two partial responses in pretreated patients. In addi-
tion, six patients had stable disease lasting from 3.7 to at least
Table 5 Synergism (indicated by combination indices) between raltitrexed (R) and SN 38, the active metabolite of CPT-11, in HCT-8 human colon cancer cells
(Aschele et al, 1995; 1996a)
Inhibition of cell proliferation (%) Sequential 4-h exposure Sequential 24-h exposure
(dose ratio) (dose ratio)
SN38-R (1:10) R-SN38 (10:1) SN38-R (1:5) R-SN38 (5:1)
50 0.42 0.46
75 0.11 0.27 - -
90 0.03 0.16 0.69 0.57
95 0.02 0.12 0.57 0.45
Combination index (Cl) is determined from regression analysis of growth inhibition data. Cl < 1 indicates synergism; Cl = 1 indicates additivity; Cl > 1 indicates
antagonism.
Table 6 Three-weekly dosages of raltitrexed and CPT-11 in combination in patients with advanced colorectal cancer
Dosage level - I II IlIl IV V VI
CPT-11 (mg m-2) 175 175 200 250 250 300 350
Raltitrexed (mgm-2) 2.0 2.6 2.6 2.6 3.0 3.0 3.0
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Table 8 Enhancement of cytotoxicity of radiation by raltitrexed or 5-FU in
human HT-29 colon cancer cells (Moertel, 1994)
Enhancement ratiosa
Euoxic Hypoxic
Treatment 2.5 Gy 5 Gy 2.5 Gy 5 Gy
Raltitrexed 1 gM 7.7 55.7 5.5 8.6
Raltitrexed 0.5gM 7.2 35.5 4.8 6.4
5-FU 10 gM 3.9 6.1 5.9 7.1
aEnhancement ratios were calculated from ratios of surviving fractions of
cells at 2.5 Gy and 5 Gy with and without adjuvant drug treatment. Values
> 1 indicate enhanced cell killing compared with radiation alone.
29 with 5-FU given by 24-h infusion on days 1, 8, 15, 22 and 29 of
each cycle, repeated every 4-5 weeks. Dosage levels are shown in
Table 7. To date, level 3 has been reached in ten patients with no
DLT and one partial response (at level 2).
Raltitrexed with radiotherapy
Ifdetected early, colon cancer may be cured by surgery; cure rates
0 o \ of 90% have been reported for Dukes' stage A or B1 (Moertel,
1994). However, rectal cancer is not as readily cured in this way
_ 0 @ O \because the close confines of the pelvic bones prevent access by
_ G o the surgeon to an adequate tumour-free margin. Because of this,
* < \ < local recurrence ofrectal cancer is common.
o o Radiotherapy is oftenprescribed in an attempt to reduce the risk
of tumour recurrence. Administration of post-operative 5-FU in
combination with radiotherapy resulted in a 15% survival advan-
tage and lower incidences of metastases and local recurrence in
one study (Mayer et al, 1989). These promising results with a TS
inhibitor, coupled with the known efficacy of raltitrexed in
0 20 40 60 80 100 advanced disease, make the use of raltitrexed as adjuvant therapy
5-FU concentration (% IC50) with radiotherapy in colorectal cancer an attractive treatment that
merits further investigation. Preclinical data, obtained in human
ole analyses of sequential exposure of HCT-8 and HT-29 HT-29 cancercells, showed that raltitrexed and5-FU both enhance
al cancer cells to 5-fluorouracil (5-FU) and raltitrexed.
c (24 h) followed by 5-FU (1 h); pattern suggests synergism. cell killing by radiation. However, raltitrexed was a more effective
ollowed by raltitrexed (24 h); pattern suggests additivity addition than 5-FU (Teicher and Coleman, 1997). Cells were
tested under euoxic and hypoxic conditions. As shown in Table 8,
raltitrexed 0.5 or 1 ,UM increased radiation-induced cell killing to a
(Schwartz et al, 1997). Most recent data from 17 markedly greaterextentthan 5-FU 10 uMundereuoxic conditions.
-ate that 70% have stable disease (some for up to 12 In the transplantable Lewis lung carcinoma cell line, raltitrexed
how a complete response in a non-pretreated patient. showed a radiation dose-modifying effect of 1.5. Raltitrexed is
een some dose delays due to neutropenia but none of believed to achieve this effect through the inhibition of repair of
patients have withdrawn from treatment. No DLT or radiation-induced DNA strand breaks in euoxic and hypoxic cells
6icity has been reported to date. and by interaction with radiation in hypoxic cells.
dphase I study is being conducted at a single German Two phase I studies in the UK are currently investigating
tients with untreated advanced or metastatic CRC. combinations of raltitrexed 2.0, 2.6 and 3.0 mg m-2 with radio-
e to determine the MTD and to assess the pharmaco- therapy (given as 28 fractions of 1.8 Gy 5 times weekly for 5-6
harmacodynamic profile of raltitrexed on days 8 and weeks) in patients with resected or inoperable/recurrent rectal
Table 7 Doses of raltitrexed (days 8 and 29) and 5-FU infusion (days 1, 8, 15, 22 and 29) in patients with advanced colorectal cancer
Dosage level (4- to 5-weekly cycles) 1 2 3 4 5 6
Raltitrexed 15-min infusion (mg m-2) 2.6 2.6 2.6 2.6 3.0 3.0
5-FU 24-h infusion (mg m-2) 1200 1600 2000 2400 2000 2400
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Figure 8 Dosing scheme for raltitrexed with radiotherapy in patients with resected rectal cancer
cancer (Figure 8). The investigators aim to recruit 18 patients to
each study to determine the optimum dosage of raltitrexed to be
used as combination treatment with radiotherapy. As in other
studies discussed, safety is being assessed in terms of adverse
event reports and haematological and biochemical parameters.
MTD has not yet been reached at level 2, and the major toxicities
to date are asthenia and diarrhoea. Interestingly, raltitrexed does
not appear to sensitize normal tissue to radiation.
CONCLUSIONS
Following the extensive monotherapy clinical trial programme in
advanced CRC, raltitrexed is now being investigated in combina-
tion with other cytotoxic agents and as adjuvant treatment for
earlier stages ofthe disease. The direct and specific mode ofaction
of raltitrexed offers exciting new opportunities for more effective
cytotoxic treatments in a range of malignancies. Initial encour-
aging results in other tumour types have led to the initiation of
monotherapy and combination studies in head and neck, prostate,
lung, breast, gastric, colorectal, ovarian and adrenal cancers, and in
paediatric malignancies and advanced soft tissue sarcoma. The
significant single-agent anti-tumour activity (comparable to modu-
lated 5-FU regimens in advanced CRC) and early evidence of
synergistic activity in combination with 5-FU and/or CPT-11 offer
for the first time the possibility of a stepped increase in the effec-
tiveness ofchemotherapy in this disease. The lack oftoxicity seen
with raltitrexed in combination with CPT-11 is both scientifically
interesting and clinically exciting, and indicates that improvements
in efficacy may be achieved with no deterioration in tolerability.
Available data from the combination studies show that all treat-
ments have been well tolerated so far. As further data emerge, it
will be possible to evaluate more fully the broad contribution of
raltitrexed to the treatment ofcancer.
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